Clinical Trials Logo

Birch Pollen Allergy clinical trials

View clinical trials related to Birch Pollen Allergy.

Filter by:

NCT ID: NCT01137357 Completed - Hay Fever Clinical Trials

Probiotics for Reduction Of Markers In Subjects With Allergy

PROMISA
Start date: November 2008
Phase: N/A
Study type: Interventional

In vitro studies reveal immunomodulatory effects of probiotic bacteria that are strain-dependent. Differential immunomodulatory in vitro capacities can not be extrapolated directly to in vivo efficacy. Thus, in vitro screening should be followed by comparative analysis of the selected immunomodulatory probiotic strains in an in vivo setting. Birch pollen allergy is one of the most common forms of respiratory allergy in European countries, and recognized by a Th2-skewed immune system. Five Lactobacillus strains will be evaluated for their immunomodulatory properties in birch pollen sensitive subjects outside the hay fever season. A double-blind placebo-controlled parallel study will be performed in which subjects with a proven birch pollen allergy will consume one of 5 different probiotic yoghurts containing 4 L. plantarum strains and 1 L. casei strain or a placebo yoghurt. Blood samples are collected at the start and after 4 weeks. Immune parameters are determined in serum and peripheral blood mononuclear cell cultures (hPBMC) derived from these subjects.

NCT ID: NCT00932607 Completed - Clinical trials for Birch Pollen Allergy

SUBLIVAC® Birch PROBE Study

Start date: July 2009
Phase: Phase 2
Study type: Interventional

Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in subjects suffering from IgE mediated allergic complaints triggered by birch pollen.

NCT ID: NCT00309062 Completed - Clinical trials for Birch Pollen Allergy

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

Start date: December 2003
Phase: Phase 3
Study type: Interventional

Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis

NCT ID: NCT00266526 Completed - Clinical trials for Birch Pollen Allergy

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Start date: July 2003
Phase: Phase 2
Study type: Interventional

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV